Details and references regarding individual diseases are provided in the Supplementary Appendix. CIDP denotes chronic inflammatory demyelinating polyneuropathy, Covid-19 coronavirus disease 2019, and ...
New findings from a Phase II study indicate that antenatal treatment with the FcRn blocker nipocalimab resulted in low fetal drug exposure and transient reductions in infant IgG levels at birth, ...
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SCOTTSDALE, Ariz. — A novel therapeutic approach ...
Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations. Farmakidis explains how ...
Viridian Therapeutics Inc. has disclosed a preclinical portfolio of neonatal Fc receptor (FcRn) inhibitors designed for next-generation treatment of antibody-mediated autoimmune diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results